Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Globe Newswire•02/10/2026•08:00 ET
0
Key Highlights
- ➤FDA clearance makes SZN-8141’s IND effective for clinical development.
- ➤First DUET patient dosing expected in fourth quarter of 2026.
- ➤Second private-placement closing expected to provide approximately $95.1 million gross proceeds.
- ➤Second closing expected around October 20, 2026, subject to closing conditions.
- ➤Initial DUET data expected in the second half of 2027.
Expert Statements
Craig Parker, Chief Executive Officer of Surrozen
“FDA clearance of the SZN-8141 IND marks an important milestone for Surrozen as we advance our Wnt-based ophthalmology pipeline into clinical development. We look forward to initiating the DUET study and evaluating SZN-8141 in patients with diabetic macular edema. Importantly, this milestone also satisfies the condition for the second closing of our March 2025 private placement, which is expected to provide approximately $95.1 million in gross proceeds to support the advancement of SZN-8141 and SZN-8143.”
First patient expected to be dosed in the DUET study in the fourth quarter of 2026
Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds
Get started
Create a free account to read the full story.